Staessen J, Kesteloot H
Eur J Clin Pharmacol. 1981 Feb;19(3):167-72. doi: 10.1007/BF00561943.
The antiarrhythmic activity of intravenous moxaprindine was evaluated in 26 patients with cardiovascular disease; the mean maximum dose was 2.5 +/- 0.12 mg/kg. Ventricular extopics were completely abolished in 19 patients and significantly reduced in four patients, but were not favourably affected in three patients. In one patient with numerous runs of ventricular tachycardia, normal sinus rhythm was restored. Coupled ventricular ectopic activity always completely disappeared. At the maximum dose, the PR-interval (+27.7 +/- 3.3%), the QRS-duration (+24.6 +/- 2.2%), the QT-interval (+17.0 +/- 1.5%) and the QTc-interval (+10.8 +/- 1.2%) were significantly prolonged. The QRS morphology essentially remained unchanged. Moxaprindine caused first degree atrioventricular block in eight patients. The sinus rate was slowed at every dosage level. Nevertheless, moxaprindine could safely be administered to patients with dysfunction of the specialized conduction system, or with a damaged myocardium. Serious side effects did not occur. Moxaprindine is a promising new antiarrhythmic drug for the treatment of ventricular arrhythmias, but its value and safely in the chronic oral treatment of these arrhythmias remain to be established.
对26例心血管疾病患者评估了静脉注射莫沙必利的抗心律失常活性；平均最大剂量为2.5±0.12mg/kg。19例患者室性早搏完全消失，4例患者显著减少，但3例患者未得到有效改善。1例有多次室性心动过速发作的患者恢复了正常窦性心律。成对室性早搏活动总是完全消失。在最大剂量时，PR间期（+27.7±3.3%）、QRS时限（+24.6±2.2%）、QT间期（+17.0±1.5%）和QTc间期（+10.8±1.2%）显著延长。QRS形态基本保持不变。莫沙必利导致8例患者出现一度房室传导阻滞。在每个剂量水平，窦性心率均减慢。然而，莫沙必利可安全地用于特殊传导系统功能障碍或心肌受损的患者。未发生严重副作用。莫沙必利是一种有前途的治疗室性心律失常的新型抗心律失常药物，但其在这些心律失常慢性口服治疗中的价值和安全性仍有待确定。
